We Acquire, Develop and Finance Undervalued Biomedical Assets
Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.
Q BioMed Announces Full Settlement of All Convertible Debt
Q BioMed Adds Boston University’s Dr. Tager-Flusberg to Advisory Committee
Q Biomed Inc. Announces Funding to Technology Partner Mannin Research Inc. to Expand Product Pipeline
OUR GROWING PIPELINE MITIGATES RISK
Topical eyedrops for glaucoma
Chemotherapeutic for liver cancer
Rare pediatric non-verbal Autism Spectrum Disorder
PRE IND 2/3
Radio-pharmaceutical for metastatic cancer bone pain
Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.
Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets. 80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.
Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.
Copyright © 2017 Q BioMed, Inc. All Rights Reserved
501 Madison Ave, 14th Floor
New York, NY 10022 USA
P: +1 888 357 2435